Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck
Purpose: To evaluate the prognostic significance of hemoglobin (Hb) levels measured before and during treatment with accelerated radiotherapy with carbogen and nicotinamide (ARCON). Methods and Materials: Two hundred fifteen patients with locally advanced tumors of the head and neck were included in...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2006, Vol.64 (1), p.83-89 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 89 |
|---|---|
| container_issue | 1 |
| container_start_page | 83 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 64 |
| creator | Hoogsteen, Ilse J. Pop, Lucas A.M. Marres, Henri A.M. Merkx, Matthijs A.W. van den Hoogen, Franciscus J.A. van der Kogel, Albert J. Kaanders, Johannes H.A.M. |
| description | Purpose: To evaluate the prognostic significance of hemoglobin (Hb) levels measured before and during treatment with accelerated radiotherapy with carbogen and nicotinamide (ARCON).
Methods and Materials: Two hundred fifteen patients with locally advanced tumors of the head and neck were included in a phase II trial of ARCON. This treatment regimen combines accelerated radiotherapy for reduction of repopulation with carbogen breathing and nicotinamide to reduce hypoxia. In these patients, Hb levels were measured before, during, and after radiotherapy.
Results: Preirradiation and postirradiation Hb levels were available for 206 and 195 patients respectively. Hb levels below normal were most frequently seen among patients with T4 (
p < 0.001) and N2 (
p < 0.01) disease. Patients with a larynx tumor had significantly higher Hb levels (
p < 0.01) than other tumor sites. During radiotherapy, 69 patients experienced a decrease in Hb level. In a multivariate analysis there was no prognostic impact of Hb level on locoregional control, disease-free survival, and overall survival. Primary tumor site was independently prognostic for locoregional control (
p = 0.018), and gender was the only prognostic factor for disease-free and overall survival (
p < 0.05). High locoregional control rates were obtained for tumors of the larynx (77%) and oropharynx (72%).
Conclusion: Hemoglobin level was not found to be of prognostic significance for outcome in patients with squamous cell carcinoma of the head and neck after oxygen-modifying treatment with ARCON. |
| doi_str_mv | 10.1016/j.ijrobp.2005.07.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67590220</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301605011636</els_id><sourcerecordid>67590220</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-f4305b49f3c389e8bfa2032de3ad474c146024b6007c1604a8c6928db6a1a33d3</originalsourceid><addsrcrecordid>eNp9kd1qGzEQhUVpaRy3b1CKrnq329Fqf28KwfQPQgwhhd4JrTS7luuVHEmb1k_Q164WG3oXGJibb87MmUPIOwY5A1Z_3Odm711_zAuAKocmB-AvyIq1TZfxqvr5kqyA15DxBF-R6xD2AMBYU74mV6wuGGfQrMjf7Z_TiDabnDbDydiRRo8yTmgj_W3ijt7cb7Z31KOeFQYad0iP3o3WhWgUDWa0ZjBKWoXUDXSHkxsPrjeWpgqPs5zcHKjCw4Eq6ZWxbpILuOjsUGoqraYW1a835NUgDwHfXvqa_Pjy-WHzLbvdfv2-ubnNVPISs6HkUPVlN3DF2w7bfpAF8EIjl7psSsXKGoqyrwEaxWooZavqrmh1X0smOdd8TT6cdZOLxxlDFJMJy33SYjpV1E3VQZE016Q8g8q7EDwO4ujNJP1JMBBLAGIvzgGIJQABjUgBpLH3F_25n1D_H7p8PAGfzgAml08GvQjKYPqfNh5VFNqZ5zf8A-htmrU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67590220</pqid></control><display><type>article</type><title>Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hoogsteen, Ilse J. ; Pop, Lucas A.M. ; Marres, Henri A.M. ; Merkx, Matthijs A.W. ; van den Hoogen, Franciscus J.A. ; van der Kogel, Albert J. ; Kaanders, Johannes H.A.M.</creator><creatorcontrib>Hoogsteen, Ilse J. ; Pop, Lucas A.M. ; Marres, Henri A.M. ; Merkx, Matthijs A.W. ; van den Hoogen, Franciscus J.A. ; van der Kogel, Albert J. ; Kaanders, Johannes H.A.M.</creatorcontrib><description>Purpose: To evaluate the prognostic significance of hemoglobin (Hb) levels measured before and during treatment with accelerated radiotherapy with carbogen and nicotinamide (ARCON).
Methods and Materials: Two hundred fifteen patients with locally advanced tumors of the head and neck were included in a phase II trial of ARCON. This treatment regimen combines accelerated radiotherapy for reduction of repopulation with carbogen breathing and nicotinamide to reduce hypoxia. In these patients, Hb levels were measured before, during, and after radiotherapy.
Results: Preirradiation and postirradiation Hb levels were available for 206 and 195 patients respectively. Hb levels below normal were most frequently seen among patients with T4 (
p < 0.001) and N2 (
p < 0.01) disease. Patients with a larynx tumor had significantly higher Hb levels (
p < 0.01) than other tumor sites. During radiotherapy, 69 patients experienced a decrease in Hb level. In a multivariate analysis there was no prognostic impact of Hb level on locoregional control, disease-free survival, and overall survival. Primary tumor site was independently prognostic for locoregional control (
p = 0.018), and gender was the only prognostic factor for disease-free and overall survival (
p < 0.05). High locoregional control rates were obtained for tumors of the larynx (77%) and oropharynx (72%).
Conclusion: Hemoglobin level was not found to be of prognostic significance for outcome in patients with squamous cell carcinoma of the head and neck after oxygen-modifying treatment with ARCON.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2005.07.003</identifier><identifier>PMID: 16213107</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Inhalation ; Adult ; Aged ; Aged, 80 and over ; ARCON ; Carbogen ; Carbon Dioxide - administration & dosage ; Carbon Dioxide - therapeutic use ; Carcinoma, Squamous Cell - blood ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - radiotherapy ; Cell Hypoxia - drug effects ; Female ; Head and neck cancer ; Head and Neck Neoplasms - blood ; Head and Neck Neoplasms - pathology ; Head and Neck Neoplasms - radiotherapy ; Hemoglobin levels ; Hemoglobins - analysis ; Humans ; Male ; Middle Aged ; Multivariate Analysis ; Niacinamide - administration & dosage ; Niacinamide - therapeutic use ; Nicotinamide ; Oxygen - administration & dosage ; Oxygen - therapeutic use ; Prognosis ; Radiation-Sensitizing Agents - administration & dosage ; Radiation-Sensitizing Agents - therapeutic use ; Sex Factors ; Squamous cell carcinoma ; Treatment Outcome</subject><ispartof>International journal of radiation oncology, biology, physics, 2006, Vol.64 (1), p.83-89</ispartof><rights>2006 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-f4305b49f3c389e8bfa2032de3ad474c146024b6007c1604a8c6928db6a1a33d3</citedby><cites>FETCH-LOGICAL-c360t-f4305b49f3c389e8bfa2032de3ad474c146024b6007c1604a8c6928db6a1a33d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2005.07.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,4012,27910,27911,27912,45982</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16213107$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoogsteen, Ilse J.</creatorcontrib><creatorcontrib>Pop, Lucas A.M.</creatorcontrib><creatorcontrib>Marres, Henri A.M.</creatorcontrib><creatorcontrib>Merkx, Matthijs A.W.</creatorcontrib><creatorcontrib>van den Hoogen, Franciscus J.A.</creatorcontrib><creatorcontrib>van der Kogel, Albert J.</creatorcontrib><creatorcontrib>Kaanders, Johannes H.A.M.</creatorcontrib><title>Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose: To evaluate the prognostic significance of hemoglobin (Hb) levels measured before and during treatment with accelerated radiotherapy with carbogen and nicotinamide (ARCON).
Methods and Materials: Two hundred fifteen patients with locally advanced tumors of the head and neck were included in a phase II trial of ARCON. This treatment regimen combines accelerated radiotherapy for reduction of repopulation with carbogen breathing and nicotinamide to reduce hypoxia. In these patients, Hb levels were measured before, during, and after radiotherapy.
Results: Preirradiation and postirradiation Hb levels were available for 206 and 195 patients respectively. Hb levels below normal were most frequently seen among patients with T4 (
p < 0.001) and N2 (
p < 0.01) disease. Patients with a larynx tumor had significantly higher Hb levels (
p < 0.01) than other tumor sites. During radiotherapy, 69 patients experienced a decrease in Hb level. In a multivariate analysis there was no prognostic impact of Hb level on locoregional control, disease-free survival, and overall survival. Primary tumor site was independently prognostic for locoregional control (
p = 0.018), and gender was the only prognostic factor for disease-free and overall survival (
p < 0.05). High locoregional control rates were obtained for tumors of the larynx (77%) and oropharynx (72%).
Conclusion: Hemoglobin level was not found to be of prognostic significance for outcome in patients with squamous cell carcinoma of the head and neck after oxygen-modifying treatment with ARCON.</description><subject>Administration, Inhalation</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>ARCON</subject><subject>Carbogen</subject><subject>Carbon Dioxide - administration & dosage</subject><subject>Carbon Dioxide - therapeutic use</subject><subject>Carcinoma, Squamous Cell - blood</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Cell Hypoxia - drug effects</subject><subject>Female</subject><subject>Head and neck cancer</subject><subject>Head and Neck Neoplasms - blood</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Head and Neck Neoplasms - radiotherapy</subject><subject>Hemoglobin levels</subject><subject>Hemoglobins - analysis</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Niacinamide - administration & dosage</subject><subject>Niacinamide - therapeutic use</subject><subject>Nicotinamide</subject><subject>Oxygen - administration & dosage</subject><subject>Oxygen - therapeutic use</subject><subject>Prognosis</subject><subject>Radiation-Sensitizing Agents - administration & dosage</subject><subject>Radiation-Sensitizing Agents - therapeutic use</subject><subject>Sex Factors</subject><subject>Squamous cell carcinoma</subject><subject>Treatment Outcome</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kd1qGzEQhUVpaRy3b1CKrnq329Fqf28KwfQPQgwhhd4JrTS7luuVHEmb1k_Q164WG3oXGJibb87MmUPIOwY5A1Z_3Odm711_zAuAKocmB-AvyIq1TZfxqvr5kqyA15DxBF-R6xD2AMBYU74mV6wuGGfQrMjf7Z_TiDabnDbDydiRRo8yTmgj_W3ijt7cb7Z31KOeFQYad0iP3o3WhWgUDWa0ZjBKWoXUDXSHkxsPrjeWpgqPs5zcHKjCw4Eq6ZWxbpILuOjsUGoqraYW1a835NUgDwHfXvqa_Pjy-WHzLbvdfv2-ubnNVPISs6HkUPVlN3DF2w7bfpAF8EIjl7psSsXKGoqyrwEaxWooZavqrmh1X0smOdd8TT6cdZOLxxlDFJMJy33SYjpV1E3VQZE016Q8g8q7EDwO4ujNJP1JMBBLAGIvzgGIJQABjUgBpLH3F_25n1D_H7p8PAGfzgAml08GvQjKYPqfNh5VFNqZ5zf8A-htmrU</recordid><startdate>2006</startdate><enddate>2006</enddate><creator>Hoogsteen, Ilse J.</creator><creator>Pop, Lucas A.M.</creator><creator>Marres, Henri A.M.</creator><creator>Merkx, Matthijs A.W.</creator><creator>van den Hoogen, Franciscus J.A.</creator><creator>van der Kogel, Albert J.</creator><creator>Kaanders, Johannes H.A.M.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2006</creationdate><title>Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck</title><author>Hoogsteen, Ilse J. ; Pop, Lucas A.M. ; Marres, Henri A.M. ; Merkx, Matthijs A.W. ; van den Hoogen, Franciscus J.A. ; van der Kogel, Albert J. ; Kaanders, Johannes H.A.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-f4305b49f3c389e8bfa2032de3ad474c146024b6007c1604a8c6928db6a1a33d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Administration, Inhalation</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>ARCON</topic><topic>Carbogen</topic><topic>Carbon Dioxide - administration & dosage</topic><topic>Carbon Dioxide - therapeutic use</topic><topic>Carcinoma, Squamous Cell - blood</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Cell Hypoxia - drug effects</topic><topic>Female</topic><topic>Head and neck cancer</topic><topic>Head and Neck Neoplasms - blood</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Head and Neck Neoplasms - radiotherapy</topic><topic>Hemoglobin levels</topic><topic>Hemoglobins - analysis</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Niacinamide - administration & dosage</topic><topic>Niacinamide - therapeutic use</topic><topic>Nicotinamide</topic><topic>Oxygen - administration & dosage</topic><topic>Oxygen - therapeutic use</topic><topic>Prognosis</topic><topic>Radiation-Sensitizing Agents - administration & dosage</topic><topic>Radiation-Sensitizing Agents - therapeutic use</topic><topic>Sex Factors</topic><topic>Squamous cell carcinoma</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoogsteen, Ilse J.</creatorcontrib><creatorcontrib>Pop, Lucas A.M.</creatorcontrib><creatorcontrib>Marres, Henri A.M.</creatorcontrib><creatorcontrib>Merkx, Matthijs A.W.</creatorcontrib><creatorcontrib>van den Hoogen, Franciscus J.A.</creatorcontrib><creatorcontrib>van der Kogel, Albert J.</creatorcontrib><creatorcontrib>Kaanders, Johannes H.A.M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoogsteen, Ilse J.</au><au>Pop, Lucas A.M.</au><au>Marres, Henri A.M.</au><au>Merkx, Matthijs A.W.</au><au>van den Hoogen, Franciscus J.A.</au><au>van der Kogel, Albert J.</au><au>Kaanders, Johannes H.A.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2006</date><risdate>2006</risdate><volume>64</volume><issue>1</issue><spage>83</spage><epage>89</epage><pages>83-89</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose: To evaluate the prognostic significance of hemoglobin (Hb) levels measured before and during treatment with accelerated radiotherapy with carbogen and nicotinamide (ARCON).
Methods and Materials: Two hundred fifteen patients with locally advanced tumors of the head and neck were included in a phase II trial of ARCON. This treatment regimen combines accelerated radiotherapy for reduction of repopulation with carbogen breathing and nicotinamide to reduce hypoxia. In these patients, Hb levels were measured before, during, and after radiotherapy.
Results: Preirradiation and postirradiation Hb levels were available for 206 and 195 patients respectively. Hb levels below normal were most frequently seen among patients with T4 (
p < 0.001) and N2 (
p < 0.01) disease. Patients with a larynx tumor had significantly higher Hb levels (
p < 0.01) than other tumor sites. During radiotherapy, 69 patients experienced a decrease in Hb level. In a multivariate analysis there was no prognostic impact of Hb level on locoregional control, disease-free survival, and overall survival. Primary tumor site was independently prognostic for locoregional control (
p = 0.018), and gender was the only prognostic factor for disease-free and overall survival (
p < 0.05). High locoregional control rates were obtained for tumors of the larynx (77%) and oropharynx (72%).
Conclusion: Hemoglobin level was not found to be of prognostic significance for outcome in patients with squamous cell carcinoma of the head and neck after oxygen-modifying treatment with ARCON.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>16213107</pmid><doi>10.1016/j.ijrobp.2005.07.003</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2006, Vol.64 (1), p.83-89 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67590220 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Administration, Inhalation Adult Aged Aged, 80 and over ARCON Carbogen Carbon Dioxide - administration & dosage Carbon Dioxide - therapeutic use Carcinoma, Squamous Cell - blood Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - radiotherapy Cell Hypoxia - drug effects Female Head and neck cancer Head and Neck Neoplasms - blood Head and Neck Neoplasms - pathology Head and Neck Neoplasms - radiotherapy Hemoglobin levels Hemoglobins - analysis Humans Male Middle Aged Multivariate Analysis Niacinamide - administration & dosage Niacinamide - therapeutic use Nicotinamide Oxygen - administration & dosage Oxygen - therapeutic use Prognosis Radiation-Sensitizing Agents - administration & dosage Radiation-Sensitizing Agents - therapeutic use Sex Factors Squamous cell carcinoma Treatment Outcome |
| title | Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T17%3A20%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxygen-modifying%20treatment%20with%20ARCON%20reduces%20the%20prognostic%20significance%20of%20hemoglobin%20in%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Hoogsteen,%20Ilse%20J.&rft.date=2006&rft.volume=64&rft.issue=1&rft.spage=83&rft.epage=89&rft.pages=83-89&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2005.07.003&rft_dat=%3Cproquest_cross%3E67590220%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67590220&rft_id=info:pmid/16213107&rft_els_id=S0360301605011636&rfr_iscdi=true |